Aromatase Inhibitor Use in Elderly Women with Hormone‑Receptor‑Positive Breast Cancer

1. Magnitude of Absolute Benefit

Standard 5‑year aromatase inhibitor (AI) therapy reduces 5‑year recurrence risk by ≈ 3.2 % absolute (from ~10 % to ~7 %). This translates to preventing recurrence in roughly 1 of 30 treated patients. 1
Extending AI therapy beyond 5 years adds an additional 1–2 % absolute reduction in recurrence risk over the next 5 years. 1

No overall‑survival advantage has been demonstrated for AI therapy in any major trial, including studies that enrolled elderly participants. 2, 3
The principal clinical gains are lower rates of distant recurrence and a 58 % relative reduction in contralateral breast cancer, not prolonged life expectancy. 2, 3

Node‑positive disease yields a 34 % relative risk reduction in recurrence, supporting AI use even in older patients. 3
High‑grade or otherwise adverse tumor pathology confers a larger absolute benefit from AI therapy. 1
Stage I, node‑negative disease with favorable features provides only a modest absolute benefit, often insufficient to outweigh toxicity. 1, 3
Patients who have undergone bilateral mastectomy lose the major AI advantage of preventing contralateral cancer, making endocrine therapy less compelling. 1

Physical role functioning deteriorates more with AI than with placebo, indicating a measurable quality‑of‑life penalty. 2, 3

A 5‑year AI course is appropriate for most older patients when the expected benefit outweighs risks. 1, 3
Routine extension beyond 5 years is discouraged in an 85‑year‑old unless the patient has node‑positive disease and excellent functional status. 1, 3
Therapy should never exceed 10 years, as additional exposure adds toxicity without clear incremental benefit. 3

Do not prescribe AI solely on the basis of hormone‑receptor positivity; the absolute benefit in very elderly patients is small. 1, 3
Assess competing mortality risks (e.g., cardiovascular disease, severe osteoporosis). When non‑cancer mortality is likely within 3–5 years, the modest recurrence reduction becomes clinically irrelevant. 1
Evaluate bone health before initiating AI; severe osteoporosis or prior fragility fractures markedly increase fracture risk with AI therapy. (Evidence from trial data, Level I).

For patients with low‑risk disease (node‑negative, small tumor, bilateral mastectomy, or significant comorbidities), the ≈ 3 % absolute recurrence benefit does not justify the toxicity burden; endocrine therapy should be omitted. 1, 3
For patients with high‑risk disease (node‑positive) and good functional status, a 5‑year AI regimen is reasonable, provided rigorous bone‑health monitoring and shared decision‑making emphasize that survival will not be improved. 1, 3

The American Society of Clinical Oncology recommends that postmenopausal women with hormone receptor-positive breast cancer receive anastrozole for 5 years as standard initial therapy, with extension to a total of 10 years recommended for node-positive disease and considered for higher-risk node-negative disease 4, 5, 6
Women with node-positive breast cancer should be offered extended aromatase inhibitor therapy for up to a total of 10 years of adjuvant endocrine treatment, as they derive the most substantial benefit from extended therapy 4, 5, 6
Many women with node-negative breast cancer may be offered extended therapy up to 10 years based on recurrence risk using established prognostic factors 4, 5, 6
Women with low-risk node-negative tumors should not routinely be offered extended therapy, as the absolute benefits are narrower and may not justify the ongoing toxicity 4, 5, 6

Women who receive extended adjuvant endocrine therapy should receive no more than 10 years of total treatment 4, 5, 6
Prevention of secondary or contralateral breast cancers is a major benefit of extended therapy and should inform the decision to pursue extended treatment 4, 5, 6
Extended therapy does not improve overall survival, but rather prevents distant recurrence and second breast cancers 4, 5, 6

Extended anastrozole therapy is associated with increased risk of bone-related adverse events, including fractures and osteoporosis 7
Cardiovascular events show a trend toward increased risk with extended aromatase inhibitor therapy (odds ratio 1.18) 7
Extended therapy carries ongoing risks and side effects, which should be weighed against the potential absolute benefits in shared decision-making with the patient 4, 5, 6
Quality of life assessments show worsening in physical role functioning compared to placebo during extended therapy 7
Intermittent letrozole provides quality of life benefits with less vaginal problems, improved sleep, better physical well-being, and improved mood compared to continuous administration, while maintaining non-inferior efficacy 8

Do not routinely extend therapy beyond 10 years total, as there is no evidence supporting benefit beyond this duration and toxicity accumulates 4, 5, 6
Do not automatically extend therapy in all node-negative patients—carefully assess recurrence risk using established prognostic factors 4, 5, 6
Do not ignore bone health monitoring—the increased fracture risk is real and requires proactive management 7